Visual Abstract

Visual Abstract
Visual Abstract.
View largeDownload slide
Keywords:
Fatigue, Chronic kidney disease, Mortality, Hospitalization , Outcomes

Background: Fatigue, although common and associated with outcomes in dialysis-dependent chronic kidney disease (CKD), has not been studied in nondialysis chronic kidney disease (CKD-ND) patients. Methods: In this longitudinal cohort of 266 outpatients with CKD-ND stages 2–5, we measured self-reported fatigue on 3 scales-Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR16), Beck Depression Inventory-I (BDI-I), and short form 12 health survey (SF-12) questionnaires and evaluated the prespecified composite of progression to dialysis initiation, death, or hospitalization after 12 months. Logistic and linear regression assessed characteristics associated with fatigue. Survival analysis measured associations of fatigue with outcomes. Results: Mean age was 64.4 ± 12.0 years, and mean estimated glomerular filtration rate (eGFR) was 31.6 ± 16.7 mL/min/1.73 m2. Fatigue was common, with 69.2% reporting fatigue on QIDS-SR16 and 77.7% on BDI-I. Unemployment, comorbidities, use of antidepressant medications, and lower hemoglobin correlated with fatigue. There were 126 outcome events. Participants that reported any versus no fatigue on QIDS-SR16 were more likely to reach the composite, hazard ratio (HR) 1.70 (95% CI 1.11–2.59), which persisted after adjusting for demographics, comorbidities, substance abuse, hemoglobin, albumin, eGFR, and calcium-phosphorus product, HR 1.63 (1.05–2.55). Fatigue severity by the SF-12 was also associated with outcomes independent of demographics, comorbidities, and substance abuse, HR per unit increase 1.18 (1.03–1.35). No association was observed with fatigue on the BDI-I. Conclusion: Fatigue affected about 2/3 of CKD-ND patients and associated with unemployment, comorbidities, antidepressant medication use, and anemia. Fatigue measured by the QIDS-SR16 and SF-12 independently predicted outcomes in CKD patients. Eliciting the presence of fatigue may be a clinically significant prognostic assessment in CKD patients.

Keywords:
Fatigue, Chronic kidney disease, Mortality, Hospitalization , Outcomes
1.
Jim HS, Sutton SK, Jacobsen PB, Martin PJ, Flowers ME, Lee SJ. Risk factors for depression and fatigue among survivors of hematopoietic cell transplantation.
Cancer
. 2016 Apr;122(8):1290–7.
2.
Bossola M, Vulpio C, Tazza L. Fatigue in chronic dialysis patients.
Semin Dial
. 2011 Sep-Oct;24(5):550–5.
3.
Barnes S, Gott M, Payne S, Parker C, Seamark D, Gariballa S, et al. Prevalence of symptoms in a community-based sample of heart failure patients.
J Pain Symptom Manage
. 2006 Sep;32(3):208–16.
4.
Jhamb M, Liang K, Yabes J, Steel JL, Dew MA, Shah N, et al. Prevalence and correlates of fatigue in chronic kidney disease and end-stage renal disease: are sleep disorders a key to understanding fatigue?
Am J Nephrol
. 2013;38(6):489–95.
5.
Overman CL, Kool MB, Da Silva JA, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study.
Clin Rheumatol
. 2016 Feb;35(2):409–15.
6.
Weisbord SD, Carmody SS, Bruns FJ, Rotondi AJ, Cohen LM, Zeidel ML, et al. Symptom burden, quality of life, advance care planning and the potential value of palliative care in severely ill haemodialysis patients.
Nephrol Dial Transplant
. 2003 Jul;18(7):1345–52.
7.
Bossola M, Di Stasio E, Antocicco M, Panico L, Pepe G, Tazza L. Fatigue Is Associated with Increased Risk of Mortality in Patients on Chronic Hemodialysis.
Nephron
. 2015;130(2):113–8.
8.
Jhamb M, Pike F, Ramer S, Argyropoulos C, Steel J, Dew MA, et al. Impact of fatigue on outcomes in the hemodialysis (HEMO) study.
Am J Nephrol
. 2011;33(6):515–23.
9.
Jhamb M, Argyropoulos C, Steel JL, Plantinga L, Wu AW, Fink NE, et al.; Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Correlates and outcomes of fatigue among incident dialysis patients.
Clin J Am Soc Nephrol
. 2009 Nov;4(11):1779–86.
10.
Almutary H, Bonner A, Douglas C. Which Patients with Chronic Kidney Disease Have the Greatest Symptom Burden? A Comparative Study of Advanced CKD Stage and Dialysis Modality.
J Ren Care
. 2016 Jun;42(2):73–82.
11.
Jain N, Carmody T, Minhajuddin AT, Toups M, Trivedi MH, Rush AJ, et al. Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes.
Am J Nephrol
. 2016;44(3):234–44.
12.
Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.
Psychol Med
. 2004 Jan;34(1):73–82.
13.
Hedayati SS, Minhajuddin AT, Toto RD, Morris DW, Rush AJ. Validation of depression screening scales in patients with CKD.
Am J Kidney Dis
. 2009 Sep;54(3):433–9.
14.
Watnick S, Wang PL, Demadura T, Ganzini L. Validation of 2 depression screening tools in dialysis patients.
Am J Kidney Dis
. 2005 Nov;46(5):919–24.
15.
Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.
Med Care
. 1996 Mar;34(3):220–33.
16.
Ju A, Unruh M, Davison S, Dapueto J, Dew MA, Fluck R, et al.; SONG-HD Fatigue Workshop Collaborators. Establishing a Core Outcome Measure for Fatigue in Patients on Hemodialysis: A Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop Report.
Am J Kidney Dis
. 2018 Jul;72(1):104–12.
17.
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.
Kidney Int
. 2011 Jul;80(1):17–28.
18.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.
J Clin Psychiatry
. 1998;59(Suppl 20):22–33; quiz 34–57.
19.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.
Ann Intern Med
. 1999 Mar;130(6):461–70.
20.
Østhus TB, Preljevic VT, Sandvik L, Leivestad T, Nordhus IH, Dammen T, et al. Mortality and health-related quality of life in prevalent dialysis patients: comparison between 12-items and 36-items short-form health survey.
Health Qual Life Outcomes
. 2012 May;10(1):46.
21.
Perez-Moreno AC, Jhund PS, Macdonald MR, Petrie MC, Cleland JG, Böhm M, et al. Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure).
JACC Heart Fail
. 2014 Apr;2(2):187–97.
22.
Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review.
Adv Chronic Kidney Dis
. 2007 Jan;14(1):82–99.
23.
Zyga S, Alikari V, Sachlas A, Fradelos EC, Stathoulis J, Panoutsopoulos G, et al. Assessment of Fatigue in End Stage Renal Disease Patients Undergoing Hemodialysis: Prevalence and Associated Factors.
Med Arh
. 2015 Dec;69(6):376–80.
24.
Wan Zukiman WZ, Yaakup H, Zakaria NF, Shah SA. Symptom Prevalence and the Negative Emotional States in End-Stage Renal Disease Patients with or without Renal Replacement Therapy: A Cross-Sectional Analysis.
J Palliat Med
. 2017 Oct;20(10):1127–34.
25.
Murphy EL, Murtagh FE, Carey I, Sheerin NS. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool.
Nephron Clin Pract
. 2009;111(1):c74–80.
26.
Senanayake S, Gunawardena N, Palihawadana P, Bandara P, Haniffa R, Karunarathna R, et al. Symptom burden in chronic kidney disease; a population based cross sectional study.
BMC Nephrol
. 2017 Jul;18(1):228.
27.
Bossola M, Luciani G, Giungi S, Tazza L. Anorexia, fatigue, and plasma interleukin-6 levels in chronic hemodialysis patients.
Ren Fail
. 2010;32(9):1049–54.
28.
Chang WK, Hung KY, Huang JW, Wu KD, Tsai TJ. Chronic fatigue in long-term peritoneal dialysis patients.
Am J Nephrol
. 2001 Nov-Dec;21(6):479–85.
29.
Ossareh S, Roozbeh J, Krishnan M, Liakopoulos V, Bargman JM, Oreopoulos DG. Fatigue in chronic peritoneal dialysis patients.
Int Urol Nephrol
. 2003;35(4):535–41.
30.
Wang SY, Zang XY, Fu SH, Bai J, Liu JD, Tian L, et al. Factors related to fatigue in Chinese patients with end-stage renal disease receiving maintenance hemodialysis: a multi-center cross-sectional study.
Ren Fail
. 2016;38(3):442–50.
31.
Karakan S, Sezer S, Ozdemir FN. Factors related to fatigue and subgroups of fatigue in patients with end-stage renal disease.
Clin Nephrol
. 2011 Nov;76(5):358–64.
32.
Bossola M, Di Stasio E, Giungi S, Rosa F, Tazza L. Fatigue is associated with serum interleukin-6 levels and symptoms of depression in patients on chronic hemodialysis.
J Pain Symptom Manage
. 2015 Mar;49(3):578–85.
33.
Chan KY, Li CW, Wong H, Yip T, Sham MK, Cheng HW, et al. Effect of erythropoiesis-stimulating agents on hemoglobin level, fatigue and hospitalization rate in renal palliative care patients.
Int Urol Nephrol
. 2014 Mar;46(3):653–7.
34.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al.; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
N Engl J Med
. 2009 Nov;361(21):2019–32.
35.
Kurella Tamura M, O’Hare AM, McCulloch CE, Johansen KL. Signs and symptoms associated with earlier dialysis initiation in nursing home residents.
Am J Kidney Dis
. 2010 Dec;56(6):1117–26.
36.
Yang XH, Zhang BL, Gu YH, Zhan XL, Guo LL, Jin HM. Association of sleep disorders, chronic pain, and fatigue with survival in patients with chronic kidney disease: a meta-analysis of clinical trials.
Sleep Med
. 2018 Nov;51:59–65.
37.
Koyama H, Fukuda S, Shoji T, Inaba M, Tsujimoto Y, Tabata T, et al. Fatigue is a predictor for cardiovascular outcomes in patients undergoing hemodialysis.
Clin J Am Soc Nephrol
. 2010 Apr;5(4):659–66.
38.
Hedayati SS, Minhajuddin AT, Afshar M, Toto RD, Trivedi MH, Rush AJ. Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death.
JAMA
. 2010 May;303(19):1946–53.
39.
Matura LA, Malone S, Jaime-Lara R, Riegel B. A Systematic Review of Biological Mechanisms of Fatigue in Chronic Illness.
Biol Res Nurs
. 2018 Jul;20(4):410–21.
40.
van de Luijtgaarden MW, Caskey FJ, -Wanner C, Chesnaye NC, Postorino M, Janmaat CJ, et al.; EQUAL study investigators. Uraemic symptom burden and clinical condition in women and men of ≥65 years of age with advanced chronic kidney disease: results from the EQUAL study.
Nephrol Dial Transplant
. 2018, [Epub ahead of print].
41.
Yang Y, Wang Y, Shi ZW, Zhu DL, Gao PJ. Association of E/E′ and NT-proBNP with renal function in patients with essential hypertension.
PLoS One
. 2013;8(1):e54513.
42.
Tsai YC, Chiu YW, Hung CC, Hwang SJ, Tsai JC, Wang SL, et al. Association of symptoms of depression with progression of CKD.
Am J Kidney Dis
. 2012 Jul;60(1):54–61.
43.
Fischer MJ, Kimmel PL, Greene T, Gassman JJ, Wang X, Brooks DH, et al.; AASK Study Group. Elevated depressive affect is associated with adverse cardiovascular outcomes among African Americans with chronic kidney disease.
Kidney Int
. 2011 Sep;80(6):670–8.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.